Genetic Dys-regulation of Astrocytic Glutamate Transporter EAAT2 and its Implications in Neurological Disorders and Manganese Toxicity

Pratap Karki, Keisha Smith, James Johnson, Michael Aschner, Eunsook Y. Lee

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Astrocytic glutamate transporters, the excitatory amino acid transporter (EAAT) 2 and EAAT1 (glutamate transporter 1 and glutamate aspartate transporter in rodents, respectively), are the main transporters for maintaining optimal glutamate levels in the synaptic clefts by taking up more than 90 % of glutamate from extracellular space thus preventing excitotoxic neuronal death. Reduced expression and function of these transporters, especially EAAT2, has been reported in numerous neurological disorders, including amyotrophic lateral sclerosis, Alzheimer’s disease, Parkinson’s disease, schizophrenia and epilepsy. The mechanism of down-regulation of EAAT2 in these diseases has yet to be fully established. Genetic as well as transcriptional dys-regulation of these transporters by various modes, such as single nucleotide polymorphisms and epigenetics, resulting in impairment of their functions, might play an important role in the etiology of neurological diseases. Consequently, there has been an extensive effort to identify molecular targets for enhancement of EAAT2 expression as a potential therapeutic approach. Several pharmacological agents increase expression of EAAT2 via nuclear factor κB and cAMP response element binding protein at the transcriptional level. However, the negative regulatory mechanisms of EAAT2 have yet to be identified. Recent studies, including those from our laboratory, suggest that the transcriptional factor yin yang 1 plays a critical role in the repressive effects of various neurotoxins, such as manganese (Mn), on EAAT2 expression. In this review, we will focus on transcriptional epigenetics and translational regulation of EAAT2.

Original languageEnglish (US)
Pages (from-to)380-388
Number of pages9
JournalNeurochemical Research
Volume40
Issue number2
DOIs
StatePublished - 2014

Fingerprint

Amino Acid Transport System X-AG
Manganese
Nervous System Diseases
Toxicity
Epigenomics
Excitatory Amino Acid Transporter 2
Glutamic Acid
Yin-Yang
Cyclic AMP Response Element-Binding Protein
Neurotoxins
Amyotrophic Lateral Sclerosis
Extracellular Space
Single Nucleotide Polymorphism
Parkinson Disease
Rodentia
Epilepsy
Schizophrenia
Alzheimer Disease
Down-Regulation
Polymorphism

Keywords

  • EAAT2
  • Manganese
  • NF-κB
  • RNA splicing
  • Single nucleotide polymorphisms
  • YY1

ASJC Scopus subject areas

  • Cellular and Molecular Neuroscience
  • Biochemistry

Cite this

Genetic Dys-regulation of Astrocytic Glutamate Transporter EAAT2 and its Implications in Neurological Disorders and Manganese Toxicity. / Karki, Pratap; Smith, Keisha; Johnson, James; Aschner, Michael; Lee, Eunsook Y.

In: Neurochemical Research, Vol. 40, No. 2, 2014, p. 380-388.

Research output: Contribution to journalArticle

@article{4958f24143c545f0b7529c71d65dc779,
title = "Genetic Dys-regulation of Astrocytic Glutamate Transporter EAAT2 and its Implications in Neurological Disorders and Manganese Toxicity",
abstract = "Astrocytic glutamate transporters, the excitatory amino acid transporter (EAAT) 2 and EAAT1 (glutamate transporter 1 and glutamate aspartate transporter in rodents, respectively), are the main transporters for maintaining optimal glutamate levels in the synaptic clefts by taking up more than 90 {\%} of glutamate from extracellular space thus preventing excitotoxic neuronal death. Reduced expression and function of these transporters, especially EAAT2, has been reported in numerous neurological disorders, including amyotrophic lateral sclerosis, Alzheimer’s disease, Parkinson’s disease, schizophrenia and epilepsy. The mechanism of down-regulation of EAAT2 in these diseases has yet to be fully established. Genetic as well as transcriptional dys-regulation of these transporters by various modes, such as single nucleotide polymorphisms and epigenetics, resulting in impairment of their functions, might play an important role in the etiology of neurological diseases. Consequently, there has been an extensive effort to identify molecular targets for enhancement of EAAT2 expression as a potential therapeutic approach. Several pharmacological agents increase expression of EAAT2 via nuclear factor κB and cAMP response element binding protein at the transcriptional level. However, the negative regulatory mechanisms of EAAT2 have yet to be identified. Recent studies, including those from our laboratory, suggest that the transcriptional factor yin yang 1 plays a critical role in the repressive effects of various neurotoxins, such as manganese (Mn), on EAAT2 expression. In this review, we will focus on transcriptional epigenetics and translational regulation of EAAT2.",
keywords = "EAAT2, Manganese, NF-κB, RNA splicing, Single nucleotide polymorphisms, YY1",
author = "Pratap Karki and Keisha Smith and James Johnson and Michael Aschner and Lee, {Eunsook Y.}",
year = "2014",
doi = "10.1007/s11064-014-1391-2",
language = "English (US)",
volume = "40",
pages = "380--388",
journal = "Neurochemical Research",
issn = "0364-3190",
publisher = "Springer New York",
number = "2",

}

TY - JOUR

T1 - Genetic Dys-regulation of Astrocytic Glutamate Transporter EAAT2 and its Implications in Neurological Disorders and Manganese Toxicity

AU - Karki, Pratap

AU - Smith, Keisha

AU - Johnson, James

AU - Aschner, Michael

AU - Lee, Eunsook Y.

PY - 2014

Y1 - 2014

N2 - Astrocytic glutamate transporters, the excitatory amino acid transporter (EAAT) 2 and EAAT1 (glutamate transporter 1 and glutamate aspartate transporter in rodents, respectively), are the main transporters for maintaining optimal glutamate levels in the synaptic clefts by taking up more than 90 % of glutamate from extracellular space thus preventing excitotoxic neuronal death. Reduced expression and function of these transporters, especially EAAT2, has been reported in numerous neurological disorders, including amyotrophic lateral sclerosis, Alzheimer’s disease, Parkinson’s disease, schizophrenia and epilepsy. The mechanism of down-regulation of EAAT2 in these diseases has yet to be fully established. Genetic as well as transcriptional dys-regulation of these transporters by various modes, such as single nucleotide polymorphisms and epigenetics, resulting in impairment of their functions, might play an important role in the etiology of neurological diseases. Consequently, there has been an extensive effort to identify molecular targets for enhancement of EAAT2 expression as a potential therapeutic approach. Several pharmacological agents increase expression of EAAT2 via nuclear factor κB and cAMP response element binding protein at the transcriptional level. However, the negative regulatory mechanisms of EAAT2 have yet to be identified. Recent studies, including those from our laboratory, suggest that the transcriptional factor yin yang 1 plays a critical role in the repressive effects of various neurotoxins, such as manganese (Mn), on EAAT2 expression. In this review, we will focus on transcriptional epigenetics and translational regulation of EAAT2.

AB - Astrocytic glutamate transporters, the excitatory amino acid transporter (EAAT) 2 and EAAT1 (glutamate transporter 1 and glutamate aspartate transporter in rodents, respectively), are the main transporters for maintaining optimal glutamate levels in the synaptic clefts by taking up more than 90 % of glutamate from extracellular space thus preventing excitotoxic neuronal death. Reduced expression and function of these transporters, especially EAAT2, has been reported in numerous neurological disorders, including amyotrophic lateral sclerosis, Alzheimer’s disease, Parkinson’s disease, schizophrenia and epilepsy. The mechanism of down-regulation of EAAT2 in these diseases has yet to be fully established. Genetic as well as transcriptional dys-regulation of these transporters by various modes, such as single nucleotide polymorphisms and epigenetics, resulting in impairment of their functions, might play an important role in the etiology of neurological diseases. Consequently, there has been an extensive effort to identify molecular targets for enhancement of EAAT2 expression as a potential therapeutic approach. Several pharmacological agents increase expression of EAAT2 via nuclear factor κB and cAMP response element binding protein at the transcriptional level. However, the negative regulatory mechanisms of EAAT2 have yet to be identified. Recent studies, including those from our laboratory, suggest that the transcriptional factor yin yang 1 plays a critical role in the repressive effects of various neurotoxins, such as manganese (Mn), on EAAT2 expression. In this review, we will focus on transcriptional epigenetics and translational regulation of EAAT2.

KW - EAAT2

KW - Manganese

KW - NF-κB

KW - RNA splicing

KW - Single nucleotide polymorphisms

KW - YY1

UR - http://www.scopus.com/inward/record.url?scp=84938967289&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84938967289&partnerID=8YFLogxK

U2 - 10.1007/s11064-014-1391-2

DO - 10.1007/s11064-014-1391-2

M3 - Article

C2 - 25064045

AN - SCOPUS:84938967289

VL - 40

SP - 380

EP - 388

JO - Neurochemical Research

JF - Neurochemical Research

SN - 0364-3190

IS - 2

ER -